Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Ophthalmological Medicine
Volume 2016, Article ID 7240209, 4 pages
Case Report

A Gel Formulation Containing a New Recombinant Form of Manganese Superoxide Dismutase: A Clinical Experience Based on Compassionate Use-Safety of a Case Report

1Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy
2Department of Neurosciences and Reproductive and Dentistry Sciences, University of Naples Federico II, 80131 Naples, Italy
3Molecular Biology and Viral Oncology Unit, Department of Experimental Oncology, National Institute of Cancer, IRCCS Foundation, Naples, Italy
4Leadhexa Inc., QB3-UCSF, San Francisco, CA, USA

Received 9 May 2016; Accepted 13 July 2016

Academic Editor: Guy Kleinmann

Copyright © 2016 Lucia Grumetto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. We report a case of bilateral posterior subcapsular cataracts (PSCs) in a 24-year-old man with an allergic conjunctivitis history caused by a long-term therapy with glucocorticoids. Case Presentation. The patient showed a visual acuity of 9/10 for both eyes. He followed a therapy with ketotifen and bilastine for four years. During the last six months before our evaluation, he was treated with chloramphenicol and betamethasone, interrupted for onset of cataracts and increased intraocular pressure. We treated him with ophthalmic gel preparation containing a new recombinant form of manganese superoxide dismutase (rMnSOD) at a concentration of 12.5 μg/mL, only for the right eye, while left eye was treated with standard protocol of Bendazac-lysine g 0.5. Conclusion. This case report shows the protective effects of rMnSOD versus PSC disease, probably due to the capacity of rMnSOD of countering free radical species.